A PHASE I RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED SINGLE-CENTER STUDY OF SAFETY AND EFFECTIVENESS OF INNATE IMMUNITY STIMULATION VIA TLR9 IN MILD COGNITIVE IMPAIRMENT OR EARLY AD

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Alzheimer's Disease
Age: Between 60 Year(s) - 85 Year(s)
Gender: Male or Female

Other Inclusion Criteria:
1. Participants must have a reliable informant or caregiver.
2. Participants must consent to APOE genotyping.

You may not be eligible for this study if the following are true:

1. Any psychiatric diagnosis that could interfere with study procedures.
2. Autoimmune disorder or antibody-mediated disease.
3. Severe asthma.
4. Immunodeficiency syndrome.
5. History of serious infection or systemic illness.
6. Use of corticosteroids or immunosuppressive drugs within 30 days of starting the study.
7. History of splenectomy.
8. Use of chloroquine within 8 weeks of study entry.
9. Contraindication for MRI imaging.
10. History of TIA, stroke or seizures within 12 months of screening.
11. Any neurological condition other than AD that could contribute to cognitive impairment.
12. Participation in any AD investigational interventional trial.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Clinical Research Studies